Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 Long-term Extension Study in Epilepsy
NCT05718817Phase 3Enrolling by invitation
- Sponsor
- Xenon Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Apr 2033
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, open-label, single-arm trial of azetukalner in focal epilepsy and tonic-clonic seizure (GTCS), sponsored by Xenon Pharmaceuticals. Primary endpoint: Adverse Events. Started Apr 2023; status: enrolling by invitation.
02
Drugs
azetukalner
03
Conditions
focal epilepsytonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NCT05718817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718817.